ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
Ticker SymbolIPA
Company nameImmunoprecise Antibodies Ltd
IPO dateJan 30, 1987
CEODr. Jennifer Lynne Bath, Ph.D.
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJan 30
AddressIndustrious 823 Congress Ave Suite 300
CityAUSTIN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code78701
Phone16048060626
Websitehttps://www.ipatherapeutics.com/
Ticker SymbolIPA
IPO dateJan 30, 1987
CEODr. Jennifer Lynne Bath, Ph.D.
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data